Darolutamide trials for Prostate cancer

All Darolutamide trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Darolutamide for Prostate cancer

• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
  NCT05818683 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 15 locations
• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
  NCT07244341 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
  NCT07406282 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 1 location
• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
  NCT07723248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
  NCT07450599 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 23 locations
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
  NCT07611110 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 132 locations
• Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
  NCT06173362 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment
  NCT07538843 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 1 location
• Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06401980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 13 locations
• Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
  NCT05762536 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
  NCT06190899 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 13 locations
• Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
  NCT07027124 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
  NCT06631521 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
  NCT06575257 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Male · 1 location
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
  NCT03903835 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 32 locations
• Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
  NCT07617272 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
  NCT06378866 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
  NCT06625970 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 6 locations
• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
  NCT07140900 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 16 locations
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
  NCT05519449 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · 36 locations
• Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
  NCT07142551 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
  NCT06282588 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 9 locations
• TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  NCT07190300 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 31 locations

Common questions

How many trials study Darolutamide for Prostate cancer?

23 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.